IP Library Granted Patent US 7,125,857
Granted Patent B2
US 7,125,857 · App. 10/010,476 · Granted Oct 24, 2006

Modulators of DNA cytosine-5 methyltransferase and methods for use thereof

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,125,857
App. No.
10/010,476
Granted
Oct 24, 2006
Kind
B2
Abstract

A synthetic oligonucleotide comprising a C-5 methylcytosine and which recognizes and binds an allosteric site on DNA methyltransferase thereby inhibiting DNA methyltransferase activity is disclosed. Also disclosed is a composition comprising a synthetic oligonucleotide of the invention. The composition is useful for inhibiting DNA methyltransferase activity, thereby inhibiting the methylation of DNA. The composition can be a pharmaceutical composition useful for treating disorders associated with methylation defects, such as cancer and certain developmental disorders. Also disclosed is a method of inhibiting methylation of DNA. The method involves contacting a DCMTase with a synthetic oligonucleotide of the invention in the presence of the DNA, thereby resulting in an enzyme/synthetic oligonucleotide complex. The presence of the complex prevents catalysis, thereby inhibiting DNA methyltransferase activity. Also disclosed is a method of treating a disorder of cell proliferation or development by administering to a subject a synthetic oligonucleotide of the invention. The inhibition of DNA methyltransferase prevents the methylation of DNA thereby treating the disorder of cell proliferation or development.

Claims (18)

1. A method of inhibiting methylation of DNA comprising contacting a DCMTase with a synthetic inhibitor molecule so as to form an enzyme/synthetic inhibitor molecule complex that contacts the DNA,

wherein the synthetic inhibitor molecule comprises a C-5-methylcytosine which recognizes and binds an allosteric site on DCMTase,

wherein the synthetic inhibitor molecule comprising the C-5-methylcytosine comprises an oligonucleotide sequence selected from the groups consisting of SEQ ID NO 10, 13, 14, or 15, thereby inhibiting methyltransferase activity.

2. A method of inhibiting proliferation of cancer cells comprising administering to a subject a synthetic inhibitor molecule that comprises a C-5-methylcytosine which recognizes and binds an allosteric site on DCMTase thereby resulting in an enzyme/synthetic inhibitor molecule complex that contact DNA,

wherein the synthetic inhibitor molecule comprising the C-5-methylcytosine comprises an oligonucleotide sequence selected from the groups consisting of SEQ ID NO 10, 13, 14, or 15, whereby the presence of the complex inhibits DCMTase-mediated methylation of DNA, thereby inhibiting proliferation of the cancer cells.

3. The method of claim 2 , wherein the cancer cell is from lung, breast, prostate, pancreas or colon.

4. The method of claim 1 , wherein the synthetic inhibitor molecule is a synthetic oligonucleotide comprising a C-5 methylcytosine and which recognizes and binds an allosteric site on DNA cytosine methyltransferase (DCMTase) thereby modulating DCMTase activity associated with the allosteric site.

5. The method of claim 2 , wherein the subject is a human.

6. The method of claim 2 , wherein the subject is an animal.

7. The method of claim 6 , wherein the animal is porcine, piscine, avian, feline, equine, bovine, ovine, caprine or canine.

8. The method of claim 2 , wherein the synthetic inhibitor molecule is a synthetic oligonucleotide.

9. The method of claim 4 , wherein the subject is a human.

10. The method of claim 4 , wherein the subject is an animal.

11. The method of claim 10 , wherein the animal is porcine, piscine, avian, feline, equine, bovine, ovine, caprine or canine.

12. The method of claim 1 , wherein the synthetic inhibitor molecule comprises an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 15.

13. The method of claim 2 , wherein the synthetic inhibitor molecule comprises an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 15.

14. The method of claim 1 , wherein the synthetic inhibitor molecule comprises an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 10, 13 or 14.

15. The method of claim 2 , wherein the synthetic inhibitor molecule comprises an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 10, 13 or 14.

Assignments (3)
CONFIRMATORY LICENSE Recorded Aug 3, 2011
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026691/0872 →
CONFIRMATORY LICENSE Recorded Apr 15, 2010
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024236/0801 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2006
From: REICH, NORBERT O.; FLYNN, JAMES
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 017645/0404 →
Continuity (3)
Division 0948507100 · Feb 3, 2000
Provisional Application 6005741100 · Aug 29, 1997
Related Publication 20030114402A1 · Jun 19, 2003